ProCE Banner Activity

Extended Follow-up of Mantle Cell Lymphoma Patients Treated With First-line Lenalidomide + Rituximab

Slideset Download
Conference Coverage
After a median follow-up of nearly 5 years, initial treatment with lenalidomide plus rituximab achieved a CR rate of 61%, with many patients in CR achieving MRD negativity.

Released: December 14, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology